Pharmacogenetics of inhaled long‐acting beta2‐agonists in asthma: A systematic review

Slob, Elise M A; Vijverberg, Susanne J. H.; Palmer, Colin N.A.; Zazuli, Zulfan; Farzan, Niloufar; Oliveri, Nadia M. B.; Pijnenburg, Mariëlle; Koppelman, Gerard H.; Zee, Anke‐Hilse Maitland‐van der

doi:10.1111/pai.12956

Cited by 39 publications

(33 citation statements)

References 71 publications

(153 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Subsequently, independent studies have examined whether the same polymorphism affects the asthma control of patients treated with LABA, but most of them conclude that treatment with LABA or combinations of LABA and ICSs does not alter asthma control, nor does it increase exacerbations in adult or in adolescent patients (Bleecker et al, 2006, 2007, 2010; Wechsler et al, 2009). Nevertheless, a recent meta-analysis in children concluded that an increased risk of asthma exacerbation was associated with the treatment of a LABA as an “add-on controller” (Turner et al, 2016) and a recent systematic review has confirmed these results, thus concluding that the ADRB2 rs1042713 variant is associated with response to LABA increasing the risk of exacerbation only in pediatric patients, but not in adults (Slob et al, 2018a). Currently, an on-going clinical trial, called PUFFIN trial, is testing the efficacy and cost-effectiveness of ADRB2 Gly16Arg polymorphism–genotype guided treatment in asthmatic children.…”

Section: Drugs Used In Asthma Treatmentmentioning

confidence: 99%

Pharmacogenetic Factors Affecting Asthma Treatment Response. Potential Implications for Drug Therapy

et al. 2019

View full text Add to dashboard Cite

Asthma is a frequent disease, mainly characterized by airway inflammation, in which drug therapy is crucial in its management. The potential of pharmacogenomics testing in asthma therapy has been, to date, little explored. In this review, we discuss pharmacogenetic factors affecting asthma treatment, both related to drugs used as controller medications for regular maintenance, such as inhaled corticosteroids, anti-leukotriene agents, long-acting beta-agonists, and the new biologic agents used to treat severe persistent asthma. In addition, we discuss current pharmacogenomics knowledge for rescue medications provided to all patients for as-needed relief, such as short-acting beta-agonists. Evidence for genetic variations as a factor related to drugs response has been provided for the following genes and groups of drugs: Inhaled corticosteroids: FCER2 ; anti-leukotriene agents: ABCC1 , and LTC4S ; beta-agonists: ADRB2 . However, the following genes require further studies confirming or rejecting association with the response to asthma therapy: ADCY9, ALOX5, ARG1, ARG2, CRHR1, CRHR2, CYP3A4, CYP3A5, CYSLTR1, CYSLTR2, GLCCI1, IL4RA, LTA4H, ORMDL3, SLCO2B1, SPATS2L, STIP1, T, TBX21, THRA, THRB , and VEGFA . Although only a minority of these genes are, at present, listed as associated with drugs used in asthma therapy, in the Clinical Pharmacogenomics Implementation Consortium gene-drug pair list, this review reveals that sufficient evidence to start testing the potential of clinical pharmacogenomics in asthma therapy already exists. This evidence supports the inclusion in pilot pharmacogenetics tests of at least four genes. Hopefully these tests, if proven useful, will increase the efficiency and the safety of asthma therapy.

show abstract

Section: Drugs Used In Asthma Treatmentmentioning

confidence: 99%

Pharmacogenetic Factors Affecting Asthma Treatment Response. Potential Implications for Drug Therapy

et al. 2019

View full text Add to dashboard Cite

show abstract

“…12 The evidence of the role of genetic variants on asthma treatment response has been summarized in some recent reviews. [13][14][15][16][17][18] Thereby, this review aims to update the current findings described in pharmacogenetic studies of pediatric asthma published from 2018 through 2019.…”

Section: Introductionmentioning

confidence: 99%

<p>Pharmacogenetics of Pediatric Asthma: Current Perspectives</p>

Pérez-García¹,

Espuela‐Ortiz²,

Lorenzo-Díaz³

et al. 2020

PGPM

View full text Add to dashboard Cite

Asthma is a chronic respiratory disease that affects 339 million people worldwide and has a considerable impact on the pediatric population. Asthma symptoms can be controlled by pharmacological treatment. However, some patients do not respond to therapy and continue suffering from symptoms, which impair the quality of life of patients and limit their daily activity. Genetic variation has been shown to have a role in treatment response. The aim of this review is to update the main findings described in pharmacogenetic studies of pediatric asthma published from

show abstract

“…In the last year, the role of different omics in asthma treatment response has been recapitulated in different reviews [16][17][18][19][20][21]. This review aims to provide an update on the latest findings in omic studies of pediatric asthma treatment response.…”

Section: Introductionmentioning

confidence: 99%

Precision Medicine in Childhood Asthma: Omic Studies of Treatment Response

Pérez-García

Herrera‐Luis

Lorenzo-Díaz

et al. 2020

IJMS

View full text Add to dashboard Cite

Asthma is a heterogeneous and multifactorial respiratory disease with an important impact on childhood. Difficult-to-treat asthma is not uncommon among children, and it causes a high burden to the patient, caregivers, and society. This review aims to summarize the recent findings on pediatric asthma treatment response revealed by different omic approaches conducted in 2018–2019. A total of 13 studies were performed during this period to assess the role of genomics, epigenomics, transcriptomics, metabolomics, and the microbiome in the response to short-acting beta agonists, inhaled corticosteroids, and leukotriene receptor antagonists. These studies have identified novel associations of genetic markers, epigenetic modifications, metabolites, bacteria, and molecular mechanisms involved in asthma treatment response. This knowledge will allow us establishing molecular biomarkers that could be integrated with clinical information to improve the management of children with asthma.

show abstract

Pharmacogenetics of inhaled long‐acting beta2‐agonists in asthma: A systematic review

Abstract: ADRB2 rs1042713 variant is most consistently associated with response to LABA in children but not adults. To assess the clinical value of ADRB2 rs1042713 in children with asthma using LABA, a randomized clinical trial with well-defined outcomes is needed.

Cited by 39 publications

References 71 publications

Pharmacogenetic Factors Affecting Asthma Treatment Response. Potential Implications for Drug Therapy

Pharmacogenetic Factors Affecting Asthma Treatment Response. Potential Implications for Drug Therapy

<p>Pharmacogenetics of Pediatric Asthma: Current Perspectives</p>

Precision Medicine in Childhood Asthma: Omic Studies of Treatment Response

Contact Info

Product

Resources

About